AXDX

Accelerate Diagnostics

AXDX42

Penny Stock

$1.53arrow_drop_down0.64%-$0.01

Penny Stock

AXDX

AXDX42

$1.53

arrow_drop_down0.64%-$0.01

Penny Stock

Performance History

Key Stats
Open	$1.56
Prev. Close	$1.54
EPS	-1.35
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$36.46M
PE Ratio	-

	LOW	HIGH
Day Range	1.50	1.58
52 Week Range	0.73	7.00

Ratios







EPS	-1.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Accelerate Diagnostics (AXDX)

Accelerate Diagnostics Inc (AXDX) is a company that specializes in developing and commercializing innovative diagnostic solutions for the detection and treatment of serious infections. The company's flagship product is the Accelerate Pheno System, which leverages genomic identification techniques to rapidly identify pathogens and determine their susceptibility to antibiotics. This groundbreaking technology has the potential to revolutionize the field of infectious disease diagnostics, allowing healthcare providers to make more informed treatment decisions and optimize patient outcomes.

The Accelerate Pheno System is designed to provide results in just a few hours, compared to traditional methods that can take days or even weeks. This rapid turnaround time is crucial in the treatment of serious infections, where delays in determining the appropriate antibiotic therapy can have dire consequences. By providing faster and more accurate diagnoses, Accelerate Diagnostics is helping to address the growing problem of antibiotic resistance and improve patient care.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Mr. Jack Phillips
Headquarters: Tucson
Employees: 179
Exchange: NASDAQ

Keep an eye on Accelerate Diagnostics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Accelerate Diagnostics 's (AXDX) price per share?

The current price per share for Accelerate Diagnostics (AXDX) is $1.53. The stock has seen a price change of -$0.01 recently, indicating a -0.65% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Accelerate Diagnostics (AXDX)?

For Accelerate Diagnostics (AXDX), the 52-week high is $7, which is 357.52% from the current price. The 52-week low is $0.73, the current price is 109.59% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Accelerate Diagnostics (AXDX) a growth stock?

Accelerate Diagnostics (AXDX) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Accelerate Diagnostics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Accelerate Diagnostics (AXDX) stock price performance year to date (YTD)?

As of the latest data, Accelerate Diagnostics (AXDX) has a year-to-date price change of -63.83%. Over the past month, the stock has experienced a price change of -11.05%. Over the last three months, the change has been 21.43%. Over the past six months, the figure is 54.55%. Looking at a longer horizon, the five-year price change stands at -99.29%.

help

Is Accelerate Diagnostics (AXDX) a profitable company?

Accelerate Diagnostics (AXDX) has a net income of -$61.62M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 21.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -288.21% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $12.06M, although specific revenue growth data is currently not available. The gross profit is $2.55M. Operating income is noted at -$54.03M. Furthermore, the EBITDA is -$40.77M.

help

What is the market capitalization of Accelerate Diagnostics (AXDX)?

Accelerate Diagnostics (AXDX) has a market capitalization of $36.47M. The average daily trading volume is 52.92K, indicating the stock's liquidity and investor engagement.